AI Article Synopsis
- - The study analyzed outcomes for patients with resectable metachronous colorectal liver metastases (CLM) following adjuvant oxaliplatin-based chemotherapy for Stage III colorectal cancer, involving 62 patients across 32 French academic centers from 2006 to 2013.
- - Despite 52% of patients receiving preoperative chemotherapy, there were no significant differences in the characteristics or treatment outcomes related to CLM between those who did and did not receive chemotherapy, with 3-year survival rates being 79.8% overall and 34.6% disease-free.
- - The findings suggest that liver resection yields favorable outcomes for limited metachronous CLM post-chemotherapy, but the benefits of pre
Article Abstract
Background: outcome of patients who develop resectable metachronous colorectal liver metastases (CLM) after adjuvant oxaliplatin-based chemotherapy for Stage III colorectal cancer (CRC) is not well defined and the value of preoperative chemotherapy is controversial.
Methods: From 2006 to 2013, all patients undergoing liver resection for Class I metachronous CLM after adjuvant oxaliplatin-based chemotherapy for CRC, across 32 French academic centers, were included.
Results: Sixty-two patients with an average of 2 ± 1 CLM were included. Thirty-two (52%) patients received preoperative chemotherapy. There was no significant difference in the characteristics of CLM between patients with or without preoperative chemotherapy. After a median follow-up of 29 months, 3-year overall and disease-free survival rates were 79.8% and 34.6%, respectively. The median disease-free survival was not different in patients with or without preoperative chemotherapy (17 vs. 35 months respectively, p = 0.112). In multivariate analysis, only CEA level > 200 ng/ml was associated with the risk of recurrence (p = 0.027; OR = 4.7, 95% CI = 1.2-18.7).
Conclusion: Liver resection provides a good outcome in patients with limited metachronous CLM after adjuvant oxaliplatin-based chemotherapy for CRC. The interest of preoperative chemotherapy is not obvious and should be tested in a prospective controlled study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jso.26885 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary extraskeletal osteosarcoma of rectal mesentery: a rare case and literature review.
World J Surg Oncol
January 2025
The Department of General Surgery, The Second Hospital of Jilin University, Changchun, 130041, China.
Background: Extraskeletal osteosarcoma (ESOS) is a rare kind of sarcoma with a low preoperative diagnosis and a poor prognosis. ESOS arising from abdominal mesentery is extremely rare. Increasing diagnostic methods and standardizing treatment protocols are crucial issues of ESOS.
View Article and Find Full Text PDFThe value of MRI in differentiating ovarian clear cell carcinoma from other adnexal masses with O-RADS MRI scores of 4-5.
Insights Imaging
January 2025
Department of Radiology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.
Objective: To assess the utility of clinical and MRI features in distinguishing ovarian clear cell carcinoma (CCC) from adnexal masses with ovarian-adnexal reporting and data system (O-RADS) MRI scores of 4-5.
Methods: This retrospective study included 850 patients with indeterminate adnexal masses on ultrasound. Two radiologists evaluated all preoperative MRIs using the O-RADS MRI risk stratification system.
Diagnostic cholangioscopy for surgical planning of extrahepatic cholangiocarcinoma.
Sci Rep
January 2025
Digestive Disease Center, CHA Bundang Medical Center, CHA University School of Medicine, 59 Yatap-ro, Seongnam-si, 13496, Gyeonggi-do, Republic of Korea.
The recent clinical outcomes of multi-regimen chemotherapy included prolonged survival and a high rate of conversion to surgery in Asian patients with advanced biliary tract cancer. The ability of single-operator cholangioscopy (SOC) to detect and stage extrahepatic cholangiocarcinoma (CCC) in intraductal lesions is becoming more important in determining the extent of surgery. The aim of this study was to evaluate the role of SOC in surgical planning for extrahepatic CCC.
View Article and Find Full Text PDFClinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases.
Eur J Surg Oncol
January 2025
Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Electronic address:
Background: The efficacy of local control for pancreatic cancer liver metastases (PCLM), including surgical treatment, remains controversial, with no consensus on the management and clinical significance of disappearing liver metastases (DLMs). This study aimed to evaluate the clinical implications of DLMs in treating PCLM after multi-agent chemotherapy, utilizing contrast-enhanced imaging modalities.
Methods: A retrospective analysis was conducted on patients who underwent curative resection for pancreatic cancer with synchronous or metachronous liver metastases between 2014 and 2023.
IMPACT OF COVID-19 PANDEMIC ON THE SURGICAL TREATMENT OF GASTRIC CANCER: A 3-YEAR ANALYSIS.
Arq Bras Cir Dig
January 2025
Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Department of Gastroenterology - São Paulo (SP), Brazil.
Background: The COVID-19 pandemic has overloaded healthcare systems worldwide. Other diseases, such as neoplasms, including gastric cancer, remained prevalent and had their treatment compromised.
Aims: The aim of this study was to evaluate the impact of the COVID-19 pandemic on the treatment of gastric cancer and adherence to the recommended preoperative COVID-19 screening protocol.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!